-+ 0.00%
-+ 0.00%
-+ 0.00%

Greenwich LifeSciences posts Phase III FLAMINGO-01 immune response data at AACR 2026

PUBT·04/20/2026 10:01:15
Listen to the news
Greenwich LifeSciences posts Phase III FLAMINGO-01 immune response data at AACR 2026
  • Greenwich LifeSciences presented already-published open-label immune response data from Phase III FLAMINGO-01 evaluating GLSI-100 at AACR Meeting 2026.
  • Early analysis showed more patients developed signs of an immune response over time, supporting activity of GLSI-100 beyond HLA-A02 subgroup.
  • Management linked immune activation to an earlier preliminary read suggesting fewer breast cancer recurrences in treated non-HLA-A02 patients.
  • Trial remained ongoing with data cleaning continuing, meaning final results could change.
  • Separate AACR poster on trial design was scheduled for April 21, with screening exceeding 1,300 patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Greenwich Lifesciences Inc. published the original content used to generate this news brief on April 20, 2026, and is solely responsible for the information contained therein.